Private company

Epizyme, Inc.

Epizyme, Inc. is an American pharmaceutical preparations company based in Wilmington.2

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersWilmington, United States2
  • Incorporated inDE3
  • Business address400 Technology Square, 4Th Floor, Cambridge, Ma 021393
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI549300TNFWF88O4U46052
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 44507402

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-635.9%Operating margin4
-671.0%Net margin4
137.5%Revenue growth, 20214
-$227.3MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue4¢$10.5M
  • Research and development48¢$131.0M
  • Selling, general and admin49¢$134.0M
  • Income tax0¢$22.0K

Out of $37.4M in revenue.4 The company lost money this year.

Financial statements

Revenue564$37.4M in 2021+367% since 2016
0$10.0M$20.0M$30.0M$40.0M2016: $8.0M$8.0M20162017: $10.0M$10.0M2017+25%2018: $21.7M$21.7M2018+117%2019: $23.8M$23.8M2019+10%2020: $15.8M$15.8M2020−34%2021: $37.4M$37.4M2021+137%
Operating income75684-$238.0M in 2021+80% since 2015
-$300.0M-$200.0M-$100.0M02015: -$132.5M-$132.5M20152016: -$111.8M-$111.8M2016−16%2017: -$136.8M-$136.8M2017+22%2018: -$128.1M-$128.1M2018−6%2019: -$177.1M-$177.1M2019+38%2020: -$225.4M-$225.4M2020+27%2021: -$238.0M-$238.0M2021+6%
Net income75684-$251.1M in 2021+90% since 2015
-$300.0M-$200.0M-$100.0M02015: -$132.4M-$132.4M20152016: -$110.2M-$110.2M2016−17%2017: -$134.3M-$134.3M2017+22%2018: -$123.6M-$123.6M2018−8%2019: -$170.3M-$170.3M2019+38%2020: -$231.7M-$231.7M2020+36%2021: -$251.1M-$251.1M2021+8%
Fiscal year2015201620172018201920202021
Revenue$8.0M5$10.0M6$21.7M6$23.8M6$15.8M4$37.4M4
Cost of revenue$5.1M4$10.5M4
Research and development$111.2M7$91.5M5$109.7M6$105.8M8$132.6M4$110.9M4$131.0M4
Selling, general and admin$44.0M8$68.3M4$125.2M4$134.0M4
Operating expenses$275.4M4
Operating income-$132.5M7-$111.8M5-$136.8M6-$128.1M8-$177.1M4-$225.4M4-$238.0M4
Income before tax-$251.1M4
Income tax$07$07-$336.0K6$57.0K8$58.0K4$114.0K4$22.0K4
Net income-$132.4M7-$110.2M5-$134.3M6-$123.6M8-$170.3M4-$231.7M4-$251.1M4
Earnings per share-$3.327-$1.935-$2.186-$1.728-$1.934-$2.294-$2.454
Earnings per share (diluted)-$3.327-$1.935-$2.186-$1.728-$1.934-$2.294-$2.454
Shares (weighted, basic)102.6M shares4
Shares (weighted, diluted)102.6M shares4

Compare Epizyme, Inc. with another company

Corporate structure

Epizyme, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Epizyme, Inc.

  • Palo Alto Investors LP Filed SC 13G/A on Epizyme, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • PRIMECAP MANAGEMENT CO/CA/ Filed SC 13G/A on Epizyme, Inc., latest Sep 8, 2022 (4 filings since Feb 8, 2022)
  • S.a. Ipsen Filed SC 13D/A on Epizyme, Inc., latest Aug 15, 2022 (2 filings since Jul 7, 2022)
  • RPI Finance Trust Filed SC 13D/A on Epizyme, Inc., latest Jun 28, 2022 (2 filings since Feb 1, 2022)
  • Redmile Group, LLC Filed SC 13G/A on Epizyme, Inc., latest Feb 14, 2022
  • VANGUARD GROUP INC Filed SC 13G/A on Epizyme, Inc., latest Feb 10, 2022
  • Epizyme, Inc. Wilmington, Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Epizyme, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$9.6M4 Dec 31, 2021$9.6M4 Dec 31, 2020+0.2%
Accumulated depreciation$8.0M4 Dec 31, 2021$7.4M4 Dec 31, 2020+8.4%
Property and equipment, net$1.5M4 Dec 31, 2021$2.2M4 Dec 31, 2020−28.2%
Operating-lease assets (leased space)$20.1M4 Dec 31, 2021$17.3M4 Dec 31, 2020+15.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$98.3M4 Dec 31, 2021$168.2M4 Dec 31, 2020−41.5%
Marketable securities, current$78.5M4 Dec 31, 2021$205.4M4 Dec 31, 2020−61.8%
Debt securities available for sale$78.5M4 Dec 31, 2021$205.4M4 Dec 31, 2020−61.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$50.0M4 Dec 31, 2021$50.0M4 Dec 31, 20200%
Accumulated amortization$7.2M4 Dec 31, 2021$3.0M4 Dec 31, 2020+138.5%
Finite-lived intangibles, net$42.8M4 Dec 31, 2021$47.0M4 Dec 31, 2020−8.8%

Leadership

Who has led Epizyme, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robert J. Gould2013–2015
  2. Robert B. Bazemore2015–2021
  3. Grant C. Bogle2022

President

  1. Robert J. Gould2013–2015
  2. Jason P. Rhodes2013–2014
  3. Robert A. Copeland2015–2017
  4. Robert B. Bazemore2015–2021
  5. Grant C. Bogle2022

Chief financial officer

  1. Jason P. Rhodes2013–2014
  2. Andrew E. Singer2015–2017
  3. Paolo Tombesi2019–2021

Chief operating officer

  1. Jerald Korn2022
201520202025
Board members and other officers (27)

Timeline

  1. Aug 16, 2022New chief executive Grant C. Bogle becomes CEO12
  2. Aug 12, 20228-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer46
  3. Aug 9, 20228-K Results of operations47
  4. Jun 27, 20228-K Entered a material agreement; Bylaws or fiscal year changed; Regulation FD disclosure48
  5. May 24, 20228-K Listing notice or transfer49
  6. May 19, 20228-K Executive or director change; Shareholder vote50
  7. May 10, 20228-K Results of operations51
  8. Apr 6, 20228-K Executive or director change52
  9. Mar 15, 20228-K Executive or director change; Regulation FD disclosure53
  10. Mar 1, 20228-K Results of operations; Exit or restructuring costs54
  11. Jan 27, 20228-K Entered a material agreement55
  12. Jan 10, 20228-K Results of operations; Other events56
  13. Dec 22, 20218-K Ended a material agreement57
  14. Sep 14, 2015New chief executive Robert B. Bazemore becomes CEO13
  15. May 30, 2013New chief executive Robert J. Gould becomes CEO14

Calendar

When it reported results

  1. Aug 9, 2022Reported quarterly or annual results47
  2. May 10, 2022Reported quarterly or annual results51
  3. Mar 1, 2022Reported quarterly or annual results54
  4. Jan 10, 2022Reported quarterly or annual results56
  5. Nov 9, 2021Reported quarterly or annual results58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

128 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 15 major events, 58 insider forms, 12 large holders, 39 other. The latest 20:

  1. Feb 14, 2023SC 13G/A EDGAR
  2. Sep 8, 2022SC 13G/A PRIMECAP MANAGEMENT CO/CA/ EDGAR
  3. Aug 23, 202215-12G EDGAR
  4. Aug 16, 2022EFFECT EDGAR
  5. Aug 16, 2022EFFECT EDGAR
  6. Aug 16, 2022EFFECT EDGAR
  7. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  8. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  9. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  10. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  11. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  12. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  13. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  14. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  15. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  16. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  17. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  18. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  19. Aug 16, 20224 FORM 4 SUBMISSION EDGAR
  20. Aug 16, 20224 FORM 4 SUBMISSION EDGAR

The 128 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

9 open-market trades by officers, directors and large owners since October 2021: 1 buys and 8 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 11, 2022Kutok JefferyChief Scientific OfficerSale2,741$0.90$2.5KForm 4
Feb 7, 2022Beaulieu JosephSee RemarksSale222$1.50$333Form 4
Feb 7, 2022Agarwal ShefaliSale1,058$1.50$1.6KForm 4
Feb 2, 2022Agarwal ShefaliSale2,639$1.37$3.6KForm 4
Feb 2, 2022Kutok JefferyChief Scientific OfficerSale2,556$1.37$3.5KForm 4
Feb 2, 2022Beaulieu JosephSee RemarksSale687$1.37$941Form 4
Jan 31, 2022RPI Finance TrustDirectorBuy22,666,667$1.50$34.0MForm 4
Jan 26, 2022Agarwal ShefaliSale2,922$2.02$5.9KForm 4
Dec 6, 2021Agarwal ShefaliSale1,780$2.93$5.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Epizyme, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREpizyme, Inc.1
  • CIK0001571498
  • Employer ID (EIN)26-13499561
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address400 Technology Square, 4Th Floor, Cambridge, MA 021391
  • Phone617-229-58721
  • Shares outstanding168,364,752 as of Aug 5, 202210
  • On EDGAR sinceMar 22, 20131
  • Filings829 in all: 4 (414), 8-K (99), 3 (52), SC 13G/A (45), 10-Q (28), CT ORDER (23), 424B5 (14), 4/A (11)1
    All 42 form types

    S-8 (11), S-8 POS (11), SC 13G (11), EFFECT (10), SC 13D/A (10), 10-K (9), DEF 14A (9), CORRESP (8), DEFA14A (7), UPLOAD (7), S-1/A (6), S-3 (5), SC 13D (5), POS AM (3), PRE 14A (3), SC 14D9/A (3), SC TO-T/A (3), 424B4 (2), S-1 (2), S-1MEF (2), SC TO-C (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 3/A (1), 424B3 (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), DRS (1), S-3ASR (1), SC 14D9 (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 1, 2022
    Quarterly report (10-Q) Aug 9, 2022
    Proxy statement (DEF 14A) Mar 30, 2022
    Latest 8-K (8-K) Aug 12, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64